Premium
Lumiracoxib Does Not Affect the Ex Vivo Antiplatelet Aggregation Activity of Low‐Dose Aspirin in Healthy Subjects
Author(s) -
Jermany J.,
Branson J.,
Schmouder R.,
Guillaume M.,
Rordorf C.
Publication year - 2005
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270005280377
Subject(s) - aspirin , placebo , concomitant , medicine , pharmacology , pharmacodynamics , ex vivo , prostacyclin , thromboxane a2 , thromboxane b2 , thromboxane , metabolite , platelet , pharmacokinetics , chemistry , in vitro , biochemistry , alternative medicine , pathology
This randomized, double‐blind, placebo‐controlled study evaluated the pharmacodynamic effects of concomitant low‐dose aspirin and lumiracoxib in healthy subjects. Participants received lumiracoxib 400 mg once daily (n = 14) or placebo (n = 14) for 11 days, with concomitant low‐dose aspirin (75 mg once daily) from days 5 to 11. Ex vivo pharmacodynamic assessments included assays of platelet aggregation and urinary thromboxane and prostacyclin metabolite profile. Arachidonic acid—stimulated platelet aggregation was reduced from 76.3% on day 4 to 4.8% on day 11 in the placebo group and from 75.8% on day 4 to 5.1% on day 11 in the lumiracoxib group. Collagen‐induced platelet aggregation was reduced from 77.5% on day 4 to 52.8% on day 11 in the placebo group and from 79.5% on day 4 to 55.9% on day 11 in the lumiracoxib group. Urinary thromboxane and prostacyclin were unaffected by lumiracoxib. In conclusion, concomitant lumiracoxib did not interfere with the cyclooxygenase‐1‐mediated antiplatelet effects of low‐dose aspirin.